← Back to Clinical Trials
Recruiting NCT05443516

NCT05443516 Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05443516
Status Recruiting
Phase
Sponsor Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Condition Lupus Nephritis
Study Type OBSERVATIONAL
Enrollment 250 participants
Start Date 2014-06-16
Primary Completion 2022-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 250 participants in total. It began in 2014-06-16 with a primary completion date of 2022-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this research project is to better understand the origin and clinical significance of two lupus-specific "genetic signatures" (IFN signature and plasma cell signature) in patient subgroups with well-defined clinical characteristics. Our aim is to correlate these genetic signatures with cell activation profiles and the production of specific cytokines in different populations from whole blood and in short-term cultures of these circulating cells.

Eligibility Criteria

Inclusion Criteria: * Fulfilment of the EULAR/ACR classification criteria of SLE. * 18 years of age or above. * Incident or Flare biopsy-proven proliferative or membranous LN Exclusion Criteria: * Antiphospholipid syndrome nephropathy (APSN). * Pregnancy at baseline (pregnancy during follow-up will not lead to exclusion). * Anticipated non-adherence to therapy. * Medical conditions interfering with outcome evaluations. * Inability to read and/or sign the informed consent form.

Contact & Investigator

Central Contact

Frédéric Houssiau, Pr

✉ frederic.houssiau@uclouvain.be

📞 +32 02 764 53 90

Principal Investigator

Frédéric Houssiau, Pr

PRINCIPAL INVESTIGATOR

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Frequently Asked Questions

Who can join the NCT05443516 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Lupus Nephritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05443516 currently recruiting?

Yes, NCT05443516 is actively recruiting participants. Contact the research team at frederic.houssiau@uclouvain.be for enrollment information.

Where is the NCT05443516 trial being conducted?

This trial is being conducted at Brussels, Belgium.

Who is sponsoring the NCT05443516 clinical trial?

NCT05443516 is sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. The principal investigator is Frédéric Houssiau, Pr at Cliniques universitaires Saint-Luc- Université Catholique de Louvain. The trial plans to enroll 250 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology